Sage Therapeutics, Inc.
SAGE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $41 | $86 | $8 | $6 |
| % Growth | -52.3% | 1,024.8% | 21.8% | – |
| Cost of Goods Sold | $9 | $2 | $1 | $1 |
| Gross Profit | $32 | $84 | $7 | $6 |
| % Margin | 77.1% | 97.5% | 89.4% | 91.2% |
| R&D Expenses | $226 | $356 | $326 | $283 |
| G&A Expenses | $216 | $275 | $228 | $183 |
| SG&A Expenses | $216 | $275 | $228 | $183 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $22 | $33 | $0 | $0 |
| Operating Expenses | $464 | $631 | $554 | $467 |
| Operating Income | -$432 | -$580 | -$547 | -$461 |
| % Margin | -1,048.3% | -670.7% | -7,116.7% | -7,306.7% |
| Other Income/Exp. Net | $32 | $38 | $14 | $3 |
| Pre-Tax Income | -$401 | -$541 | -$533 | -$458 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$401 | -$541 | -$503 | -$451 |
| % Margin | -971.5% | -626.3% | -6,547.8% | -7,146.9% |
| EPS | -6.59 | -9.05 | -8.49 | -7.68 |
| % Growth | 27.2% | -6.6% | -10.5% | – |
| EPS Diluted | -6.59 | -9.05 | -8.49 | -7.68 |
| Weighted Avg Shares Out | 61 | 60 | 59 | 59 |
| Weighted Avg Shares Out Dil | 61 | 60 | 59 | 59 |
| Supplemental Information | – | – | – | – |
| Interest Income | $32 | $39 | $14 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $4 |
| EBITDA | -$409 | -$545 | -$546 | -$457 |
| % Margin | -992.9% | -630.5% | -7,102.1% | -7,240.4% |